Intercept Pharmaceuticals
Presencia
Ellos se encuentran en:
- Holding50%
- Biotecnología50%
Ejecutivos
Ver el organigrama con sus 27 ejecutivos principales
Biografías más buscadas en Intercept Pharmaceuticals
- Jerome Durso, Director, President and Chief Executive Officer
- Nancy Miller-Rich, Director
- Luca Benatti, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Intercept Pharmaceuticals.
Biotecnología
Genextra tiene 2.290 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Delphia Therapeutics acaba de anunciar una recaudación de fondos de 67 millones de dólares. (publicado el 7 de mayo de 2024).
- Karius acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 3 de mayo de 2024).
- Transcarent acaba de anunciar una recaudación de fondos de 126 millones de dólares. (publicado el 2 de mayo de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Intercept Pharmaceuticals
- Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update | Intercept Pharmaceuticals, Inc.
- Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022 | Intercept Pharmaceuticals, Inc.
- Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) | Intercept Pharmaceuticals, Inc.
- Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. | Intercept Pharmaceuticals, Inc.
- Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022 | Intercept Pharmaceuticals, Inc.
- Intercept Provides Update on NASH Regulatory Timeline | Intercept Pharmaceuticals, Inc.
- Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC | Intercept Pharmaceuticals, Inc.
- Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis | Intercept Pharmaceuticals, Inc.
- Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update | Intercept Pharmaceuticals, Inc.
- Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments | Intercept Pharmaceuticals, Inc.
- View more press releases Close
Redes sociales sobre Intercept Pharmaceuticals
- Intercept Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Intercept Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Jerome Durso 
Llame a Intercept Pharmaceuticals al +1 646...
